Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Prostatic Neoplasms 9Breast Neoplasms 9Osteoporosis 4Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Unspecified Childhood Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Recurrence 1Polycystic Ovary Syndrome 1Paraganglioma, Extra-Adrenal 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Metabolic Syndrome 1Menstruation Disturbances 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Hepatoblastoma 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × Absorptiometry, Photon × Clear all
NCT00401011 2018-02-23

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

AEterna Zentaris

Phase 1/2 Completed
84 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡